Despite Early Promise GLP-1 Disappoints in Parkinson’s ...Middle East

Medscape - News
Despite Early Promise GLP-1 Disappoints in Parkinson’s
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Despite Early Promise GLP-1 Disappoints in Parkinson’s )

Also on site :